Study type: In vivo/preclinical · Status: Verified against declared source

Vasoactive intestinal chemical sequence exerts therapeutic action by regulating PTEN in a model of Sjögren's disease.

Immunity, inflammation and disease · 2023

Study scale: In this study, we used NOD mice as the SS model and administered with VIP via intraperitoneal injection.

Abstract only: Open source record

Product or molecular entity relationships

VIP: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

The method of water intake and saliva flow rate were measured as published.

Methods

The method of water intake and saliva flow rate were measured as published.

Scale or participants

In this study, we used NOD mice as the SS model and administered with VIP via intraperitoneal injection.

Key findings

Nonobese diabetic (NOD) mice and the primary splenic lymphocyte cells (SPLCs) were used to construct the SS model.

Limitations and uncertainty

As a prosecretory and vasodilating neuropeptide, the vasoactive intestinal peptide (VIP) has potent immunomodulatory effects on T cells.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.